Formosa Pharmaceuticals Investors
Financials
Consolidated Financial Statements
Parent Company Only Financial Statements
News Highlight
Formosa Pharmaceuticals and AimMax Therapeutics Announce the NDA Submission to the US FDA for APP13007 for the Treatment of Post-Operative Inflammation and Pain following Ocular Surgery
2023-05-05
May 5th, 2023 TAIPEI, Taiwan – Formosa Pharmaceuticals, Inc. (6838.TWO) and AimMax Therapeutics, Inc. (United States) announce the submission of a New Drug Application to the United States Food &
